Pharmaceutical manufacturing is moving into a phase where digitalization is expected to do far more than just streamline documentation and reporting. Regulatory authorities and industry organizations are increasingly linking advanced manufacturing to tighter process control, greater efficiency, improved product quality, and more reliable supply chains. The FDA characterizes this as the adoption of new or innovatively applied technologies that can boost quality, increase efficiency, address drug shortages, and accelerate time-to-market. Similarly, ISPE’s Pharma 4.0 framework views digitalization as a means to foster transparency, adaptability, faster decision-making, and real-time in-line control across operations, quality, and compliance.
Within this landscape, connected equipment, sensors, monitoring platforms, and analytics are becoming integral to production control. IoT-enabled monitoring can facilitate deviation detection, predictive alerts, environmental control, and process visibility throughout the production floor. The true value lies not in accumulating data for its own sake, but in converting equipment and process signals into earlier, more informed responses.
For pharmaceuticals, every operational signal can also serve as a quality and compliance indicator. When equipment behavior, process parameters, and quality data are captured with proper context, teams can shift from reactive investigation to more proactive control. This is the essence of smart manufacturing in pharma: moving from simply observing what happens on the production line to acting on it with stronger evidence.
Beyond paperless manufacturing: Why equipment and process data matter
Once connected monitoring is embedded in production control, the next consideration is whether the data is sufficiently detailed, contextualized, and reliable to deliver genuine operational insight. Paperless manufacturing was a significant milestone in pharma digitalization, but it does not equate to a fully data-driven production model. The next level involves deeper visibility into equipment behavior, process performance, and the early signs of deviation or instability.
This subject will be examined at AUTOMA+ 2026 in the presentation “Beyond Paperless Manufacturing: Advancing Insights into Equipment and Process Data in Bachem’s Digital Peptide Factory” by Sonja Peter, Global MES Project Manager at Bachem AG (AUTOMA+ 2026 Partner). The case centers on Bachem’s new large-scale peptide manufacturing facility, where end-to-end data connectivity links production layers from ERP through MES and DCS to the historian, and back into MES. This closed loop enables process values, alarms, and events to be captured, contextualized, and made available for analytics.
The case also demonstrates that scaling AIoT in pharma manufacturing requires more than sensors or dashboards. Reliable data pipelines, OT/IT integration, contextualized alarms, interoperability between systems, and validated workflows are all critical. In Bachem’s example, equipment messages are classified, alarm patterns are clustered, and recurring behaviors are identified to support root-cause analysis, anomaly detection, and earlier troubleshooting. This is where the digital pharma factory evolves into a system that can help teams understand what is happening, why it is happening, and where action may be needed.
From strategy to shopfloor: Connecting performance data with operations
As equipment and process data become more accessible, the challenge becomes organizational as well as technical. A strategy can define goals around quality, efficiency, uptime, or batch performance, but those goals only become meaningful when they are translated into measurable operating signals.
This executive perspective will be addressed at AUTOMA+ 2026 by Mikko Kämäräinen, PMO and Operational Excellence Director at FinVector Oy, through the presentation “From Strategy to Shopfloor: Digitising the Performance Cascade.” The topic focuses on how manufacturing priorities can be converted into shopfloor performance logic. In practice, this means leveraging connected production data to align management targets with actual operating conditions: where downtime occurs, how deviations affect output, whether quality signals are visible early enough, and how teams can respond before performance gaps escalate into larger operational problems.
In this sense, the performance cascade is more than a management concept – it is where AIoT, shopfloor digitalization, and pharma manufacturing KPIs converge. Connected monitoring becomes a feedback loop between strategy and daily production reality, helping teams assess whether operational performance is aligned with the goals set at the business level.
Digitalized production lines: Where AIoT becomes practical
At the line level, connected monitoring integrates equipment status, sensors, process parameters, automation systems, and analytics into a single operating picture, enabling digital manufacturing to support faster troubleshooting with less manual intervention.
The production-line perspective will be brought into focus at AUTOMA+ 2026 in the presentation “Innovation Solutions in Practice: Digitalized Manufacturing with the MASIRA Production Line” by Ernst Schranz, CEO at GRITEC AG (AUTOMA+ 2026 Session Sponsor). MASIRA is a concrete example of digital manufacturing in practice. According to GRITEC, the platform is designed for 100% inline, non-destructive testing of medical consumables, including products such as pipettes, measuring beakers, and sample containers. Its architecture includes modules for testing, stacking, line control, primary packaging, transport infrastructure, and full-view checks, with line control integrating the modules and interfacing with GRITEC’s INVISTA digitalization platform.
For pharma and medical manufacturing, the operational detail matters. MASIRA is developed for cleanroom applications, supports complete product traceability, and assigns testing and measurement values to the specific mold cavity used for production. GRITEC also notes that even with 64 cavities and a 20% scrap rate, MASIRA maintains a 5.5-second cycle time. This kind of digitalized production line use case illustrates why AIoT is becoming relevant beyond pilot projects: it connects automation, monitoring, quality control, and traceability in a real manufacturing environment.
Why these questions matter for AUTOMA+ 2026
The next phase of pharma digitalization will not be defined by a single tool or platform. It will depend on how effectively companies can connect production data, operational targets, and real manufacturing constraints into systems that support better decision-making.
For pharma teams working across manufacturing, automation, digitalization, quality, engineering, and IT, AUTOMA+ 2026 brings these questions together in one setting. The Congress provides a forum for implementation experience, practical case studies, and the operational realities behind AIoT adoption, making the discussion relevant not only to digital strategy, but to how modern pharma production is measured, controlled, and improved.
Join AUTOMA+ 2026 to explore how pharma companies are applying AIoT, IoT-driven monitoring, and digital manufacturing technologies in real production settings.
Comment on this article via X: @IoTNow_ and visit our homepage IoT Now
